2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
2009
Carcinoma, Non-Small-Cell Lung
1222
Breast Neoplasms
1214
Leukemia, Myeloid, Acute
965
Neoplasm Metastasis
900
Melanoma
777
Colorectal Neoplasms
749
Lymphoma
725
Multiple Myeloma
723
Ovarian Neoplasms
673
Pancreatic Neoplasms
664
Prostatic Neoplasms
657
Lymphoma, Non-Hodgkin
657
Recurrence
636
Precursor Cell Lymphoblastic Leukemia-Lymphoma
583
Lung Neoplasms
559
Leukemia, Lymphocytic, Chronic, B-Cell
555
Glioblastoma
527
Leukemia
485
Lymphoma, Large B-Cell, Diffuse
440
Lymphoma, Follicular
418
Brain Neoplasms
413
Squamous Cell Carcinoma of Head and Neck
388
Stomach Neoplasms
386
Carcinoma, Renal Cell
384
Myelodysplastic Syndromes
381
Carcinoma, Hepatocellular
367
Advanced Solid Tumors
356
Lymphoma, Mantle-Cell
345
Glioma
342
Interventions
pembrolizumab
1
bemarituzumab
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Squamous-Cell Non-Small-Cell Lung Cancer
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts